CliffBio
small molecule

CTEXLI

CHENODIOL

Loss of exclusivityFebruary 2032FDA regulatory exclusivity expiry
CompanyMirum Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameCTEXLI
Active ingredientCHENODIOL
Strength250MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-523February 2032
NPFebruary 2028

More from Mirum Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

CTEXLI patent cliff — loss of exclusivity February 2032 | CliffBio